Clinic
ST Joseph Regional Health Center
ST Joseph Regional Health Center was paid $7.77M by Medicaid between Jan 2019 and Dec 2024, across 89 billing codes. Its largest line is 99284, emergency room visit (serious) — 53% of everything it billed.
33Billing provider infoST JOSEPH REGIONAL HEALTH CENTER
BRYAN, TX 77802
BRYAN, TX 77802
33aNPI1942294939assigned 09/06/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$7.77M
24GClaims169,053
24DCodes billed89
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#59 of 320
Median peer was paid$205K
This provider vs. median38×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 258 | $10K | |
| 2020 | 5,112 | $123K | |
| 2021 | 46,552 | $1.94M | |
| 2022 | 54,502 | $2.68M | |
| 2023 | 44,232 | $2.22M | |
| 2024incomplete | 18,397 | $789K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 53% | 14,726 | 13,631 | $4.08M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 31,499 | 29,961 | $1.38M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.0% | 9,568 | 6,937 | $467K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.8% | 2,622 | 2,394 | $454K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2.6% | 1,243 | 1,199 | $204K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.2% | 8,959 | 6,365 | $174K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 3,247 | 3,140 | $157K |
| 80053 | Comprehensive metabolic panel | 1.9% | 17,621 | 15,616 | $150K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 4,690 | 4,373 | $148K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 18,491 | 16,257 | $118K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 4,472 | 4,033 | $112K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 3,310 | 3,232 | $82K |
77 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,595 | $35K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 321 | $26K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 16 | $25K |
| 87070 | <1% | 1,675 | $23K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 751 | $15K |
| 81001 | <1% | 5,950 | $14K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 33 | $11K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 128 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 424 | $10K |
| 83690 | <1% | 2,132 | $10K | |
| 87430 | <1% | 262 | $7K | |
| 84484 | <1% | 2,120 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 57 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,937 | $5K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 24 | $4K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,777 | $4K |
| 84702 | <1% | 302 | $3K | |
| 87428 | <1% | 99 | $3K | |
| 83880 | <1% | 726 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,774 | $2K |
| 87081 | <1% | 193 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 155 | $2K |
| 84703 | <1% | 273 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,657 | $1K |
| 81025 | <1% | 174 | $1K | |
| 83735 | <1% | 906 | $916.52 | |
| 94760 | <1% | 147 | $909.73 | |
| 80061 | Lipid panel | <1% | 2,115 | $899.93 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 67 | $894.73 |
| 82550 | <1% | 274 | $845.14 | |
| 83605 | <1% | 438 | $830.30 | |
| 86900 | <1% | 420 | $649.21 | |
| 81003 | <1% | 698 | $567.29 | |
| 88300 | <1% | 27 | $566.46 | |
| 86901 | <1% | 407 | $523.84 | |
| 87077 | <1% | 601 | $453.23 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,595 | $450.29 |
| 0240U | <1% | 271 | $411.27 | |
| 87186 | <1% | 552 | $383.32 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 31 | $356.74 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 303 | $325.64 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 53 | $289.66 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 27 | $213.76 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 590 | $213.47 |
| 84100 | <1% | 441 | $168.97 | |
| 85610 | <1% | 375 | $155.13 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 363 | $150.67 |
| G0008 | Administration of influenza virus vaccine | <1% | 168 | $143.43 |
| 86850 | <1% | 16 | $140.85 | |
| 82728 | <1% | 196 | $137.40 | |
| 84550 | <1% | 303 | $133.24 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 322 | $125.41 |
| 51701 | <1% | 14 | $123.02 | |
| 87040 | <1% | 42 | $121.38 | |
| 82248 | <1% | 142 | $118.50 | |
| 83615 | <1% | 142 | $101.40 | |
| 82247 | <1% | 23 | $84.40 | |
| 85730 | <1% | 122 | $80.30 | |
| 83540 | <1% | 117 | $65.16 | |
| 85027 | <1% | 141 | $65.16 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 116 | $42.58 |
| 83550 | <1% | 43 | $36.70 | |
| 83970 | <1% | 12 | $34.68 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 401 | $23.46 |
| 84439 | <1% | 100 | $22.74 | |
| 90686 | <1% | 24 | $11.80 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $9.90 |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,007 | $6.79 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 93 | $0.00 |
| 82565 | 0% | 12 | $0.00 | |
| 90662 | 0% | 58 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 80 | $0.00 |
| 82962 | 0% | 439 | $0.00 | |
| 82043 | 0% | 145 | $0.00 | |
| 0031A | 0% | 21 | $0.00 | |
| 82607 | 0% | 13 | $0.00 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOSTWICK, MONTE (CEO)